Bacterial lysate - Lallemand Pharma

Drug Profile

Bacterial lysate - Lallemand Pharma

Alternative Names: Antibacterial vaccine sublingual - Lallemand Pharma; Bactovax; Bromunyl; Immubron; Ismigen; PIR-05; PMBL - Lallemand Pharma; Provax; Pulmigen; Respibron; Sublingual antibacterial vaccine - Lallemand Pharma

Latest Information Update: 13 Oct 2015

Price : $50

At a glance

  • Originator Lallemand Pharma
  • Class Antibacterials; Vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Chronic obstructive pulmonary disease; Respiratory tract infections
  • Phase III Allergic asthma

Most Recent Events

  • 24 Mar 2014 No development reported - Preregistration for Respiratory tract infections in Russia (Sublingual)
  • 09 Sep 2013 Phase-III clinical trials in Allergic asthma (in children and adolescents) in Poland (Sublingual)
  • 25 Jun 2012 Launched for Respiratory tract infections in Ukraine (Sublingual)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top